Daxxify (daxibotulinumtoxinA) Cost in Pennsylvania

Daxxify (daxibotulinumtoxinA) in Pennsylvania costs $480 to $850 in 2026, with a state-wide median of $600. Pricing varies by metro - typically $630 in Philadelphia and $570 in Pittsburgh. Pennsylvania pricing is at the national average.

Pittsburgh typically has the lowest daxxify (daxibotulinumtoxina) pricing in Pennsylvania, with a median of $570 (0.95x national average). Mid-size markets generally run lower than major coastal or wealthy suburban areas.

Philadelphia typically has the highest daxxify (daxibotulinumtoxina) pricing in Pennsylvania, with a median of $630 (1.05x national average). Larger metro areas with higher cost of living and more specialty providers tend to command premium pricing.

Insurance coverage for daxxify (daxibotulinumtoxina) varies by plan and state. Pennsylvania follows federal coverage standards for FDA-approved indications. Many cash-pay injectables procedures are not covered.

Pennsylvania pricing is at the national average. The state cost index is 1.00x the national average. Higher-cost states include California, New York, Massachusetts, and Washington DC; lower-cost states include Oklahoma, Mississippi, Kentucky, and Indiana.

Per unit: $16-$22 in US. Glabellar treatment (20 units): $480-$660. Full face (forehead + glabellar + crows feet, 40-60 units): $720-$1,200. Daxxify is premium-priced vs Botox ($14-$20/unit) reflecting the longer duration.

Clinical trials showed median duration of 6 months at the glabellar site (vs 3-4 months for other neuromodulators). Individual patient duration varies: some patients see 6+ months, others see closer to 4-5 months. Real-world median in 2026 is approximately 4-5 months at glabellar, slightly shorter at other facial sites.

Daxxify: 6-month median duration in trials, $16-$22/unit, peptide excipient. Botox: 3-4 month duration, $14-$20/unit, human serum albumin excipient. For patients wanting fewer treatments per year and budget tolerates premium, Daxxify is the practical choice. For cost-conscious patients comfortable with 3-4x annual treatments, Botox remains the value option.

Safety profiles are comparable. Both are FDA-approved with established clinical use. Daxxify is newer with less long-term human use data; Botox has 23+ years of cosmetic use. Common side effects (bruising, headache, eyelid heaviness) similar across all neuromodulators.

Daxxify is FDA-approved for cosmetic glabellar lines only. Botox is FDA-approved for chronic migraine. Off-label Daxxify use for migraines exists but most migraine prescribers stick with Botox where insurance coverage is established.